Antiviral metabolites from Passiflora edulis : An in vitro, phytochemical, and computational studies
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.202400853 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Abeer H Elmaidomy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt. Hauptthemen laut MEDLINE: Antiviral Agents, Passiflora, Phytochemicals, Plant Extracts. Die Arbeit nennt 47 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Yellow fever (YF) is a mosquito‐borne virus with high mortality rates, affecting regions in South America and Africa. Despite the effectiveness of YF vaccines, increased global demand and reports of rare, severe side effects have spurred the search for safer therapeutic alternatives. Current treatments lack specific antiviral drugs approved for YF, underscoring the need for new, effective therapies. This study investigated the potential of Passiflora edulis f. edulis leaf and stem extracts as antiviral agents against the yellow fever virus (YFV). In vitro tests showed that the extracts significantly reduced YFV viral loads by twofold in Huh‐7 cells and 1.5‐fold in Vero‐h‐Slam cells at a concentration of 50 µg/mL, with a smaller reduction at 25 µg/mL and no cytotoxic effects on either cell line. Phytochemical analysis identified a new C‐deoxyhexosyl flavone, luteolin‐8‐(1‐ C ‐β‐boivinopyranosyl)‐4′1‐ O ‐β‐ d ‐glucopyranoside, along with several known compounds. Protein–protein interaction (PPI) network analysis using the STRING database and Cytoscape software revealed key hub genes, including IFNA1, IL7R, CD19, IL2RA, and IFNG, crucial in antiviral defense. Molecular docking studies further evaluated how these compounds interact with the YFV NS2B‐NS3 protease, essential for viral replication. Molecular dynamics (MD) simulations confirmed the stability of these interactions over a 120‐nanosecond period, supporting the compounds’ antiviral potential. This study demonstrates the promise of Passiflora edulis metabolites as a foundation for developing novel YFV therapies by combining computational and experimental insights.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
- Institute for Virology and Immunobiology, University of Würzburg, Wuerzburg, Germany.
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
- Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Deraya University, Minia, Egypt.
- Deraya Center for Scientific Research, Deraya University, Minia, Egypt.
Förderung
- None
Zitieren
APA
Elmaidomy, A. H., Teutsch, M., Bodem, J., Bedaiwi, R. I., Alzubaidi, M. A., Abou-Zied, H. A., & Abdelmohsen, U. R. (2025). Antiviral metabolites from Passiflora edulis : An in vitro, phytochemical, and computational studies. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400853
Vancouver
Elmaidomy AH, Teutsch M, Bodem J, Bedaiwi RI, Alzubaidi MA, Abou-Zied HA, et al. Antiviral metabolites from Passiflora edulis : An in vitro, phytochemical, and computational studies. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400853
BibTeX
@article{Elmaidomy2025,
author = {Elmaidomy, Abeer H and Teutsch, Michelle and Bodem, Jochen and Bedaiwi, Ruqaiah I and Alzubaidi, Mubarak A and Abou-Zied, Hisham A and Abdelmohsen, Usama Ramadan},
title = {Antiviral metabolites from Passiflora edulis : An in vitro, phytochemical, and computational studies},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.202400853}
}
EUVIMED